Logo

AUPH

Aurinia Pharmaceuticals Inc.

AUPH

Aurinia Pharmaceuticals Inc. • NASDAQ
$16.11 ▼ -1.59% (-0.26)
Market Cap $2.12 B
52w High $16.48
52w Low $6.55
Dividend Yield 0%
P/E 28.77
Volume 860.82K
Outstanding Shares 131.84M

Income Statement

Period Revenue Operating Expense Net Income Net Profit Margin Earnings Per Share EBITDA
Q3-2025 $73.468M ▲ $35.219M ▼ $31.551M ▲ 42.945% ▲ $0.24 ▲ $36.827M ▲
Q2-2025 $70.008M ▲ $42.81M ▲ $21.513M ▼ 30.729% ▼ $0.16 $28.137M ▼
Q1-2025 $62.465M ▲ $32.044M ▼ $23.344M ▲ 37.371% ▲ $0.16 ▲ $30.272M ▲
Q4-2024 $59.867M ▼ $55.984M ▲ $1.429M ▼ 2.387% ▼ $0.01 ▼ $7.181M ▼
Q3-2024 $67.771M $49.988M $14.35M 21.174% $0.1 $20.908M

Balance Statement

Period Cash & Short-term Total Assets Total Liabilities Total Equity
Q3-2025 $351.808M ▲ $527.528M ▲ $161.757M ▼ $365.771M ▲
Q2-2025 $315.133M ▲ $502.562M ▼ $167.261M ▲ $335.301M ▼
Q1-2025 $312.901M ▼ $504.85M ▼ $154.66M ▼ $350.19M ▼
Q4-2024 $358.476M ▲ $550.645M ▲ $173.167M ▲ $377.478M ▼
Q3-2024 $348.747M $549.361M $161.359M $388.002M

Cash Flow Statement

Period Net Income Cash From Operations Cash From Investing Cash From Financing Net Change Free Cash Flow
Q3-2025 $31.551M ▲ $44.449M ▲ $-13.772M ▼ $-10.49M ▲ $20.187M ▲ $44.384M ▲
Q2-2025 $21.513M ▼ $44.241M ▲ $-13.273M ▼ $-44.394M ▲ $-13.426M ▲ $44.143M ▲
Q1-2025 $23.344M ▲ $1.3M ▼ $31.032M ▼ $-49.337M ▼ $-17.005M ▼ $1.283M ▼
Q4-2024 $1.429M ▼ $30.114M ▲ $39.223M ▲ $-23.046M ▼ $46.291M ▲ $30.058M ▲
Q3-2024 $14.35M $17.029M $-10.572M $-2.722M $3.735M $16.944M

Revenue by Products

Product Q4-2024Q1-2025Q2-2025Q3-2025
License Collaboration and Royalty Revenue
License Collaboration and Royalty Revenue
 $0 ▲$0 ▲$0 ▲$0 ▲
Product
Product
 $60.00M ▲$60.00M ▲$70.00M ▲$70.00M ▲

Five-Year Company Overview

Income Statement

Income Statement Aurinia has moved from being a loss‑making biotech to generating a small profit. Revenue has grown steadily for several years as its main drug gains traction, and margins have improved with scale. Operating losses have narrowed each year and recently flipped to a slight operating profit, helped by better cost control and growing product sales. Net income and earnings per share are now positive, but still modest, so the business is in an early profitability phase rather than being a mature, cash‑generative pharma name. The key question going forward is whether current revenue growth can continue strongly enough to support and expand this new profitability.

Balance Sheet

Balance Sheet The balance sheet looks reasonably solid for a small biotech. Total assets have been broadly stable, and shareholder equity has held steady, which suggests the company has not been heavily diluted or over‑levered recently. Debt levels are low relative to the size of the business, though they have ticked up a bit, so leverage is something to watch but not currently a major concern. Cash reserves were much higher a few years ago and have since drawn down, then stabilized, reflecting the shift from heavy investment and launch spending to a more balanced commercial footing. Overall, the company appears financially sound but not flush, with limited room for major missteps without fresh capital or stronger cash generation.

Cash Flow

Cash Flow The cash flow story has improved meaningfully. A few years ago, Aurinia was burning cash from operations as it invested in launching its drug and building out its commercial infrastructure. Operating cash flow has gradually improved and has recently turned positive, which is an important milestone for any biotech transitioning to a commercial stage. Free cash flow mirrors this pattern and is now slightly positive as well, helped by very light capital spending needs. While the cash flows are still relatively small and could swing back if spending rises or sales disappoint, the trend toward self‑funding operations is a clear financial strength compared with many early‑stage peers.

Competitive Edge

Competitive Edge Aurinia occupies a focused but attractive niche in autoimmune kidney disease, anchored by its flagship drug for lupus nephritis. Being the first approved oral therapy in this indication gives it a clear first‑mover edge and strong visibility with specialists. The drug’s convenience, differentiated mechanism, and lack of routine drug‑level monitoring set it apart from injectable biologic competitors. Strong patent protection extending over a long period further supports its market position and pricing power. However, the company is still largely dependent on a single commercial product, which concentrates risk, and it competes against much larger pharmaceutical players with deeper sales and development resources. Market share gains, physician adoption, and potential new entrants remain key uncertainties.

Innovation and R&D

Innovation and R&D Aurinia’s story is driven by innovation in autoimmune disease. Its approved drug uses a modified version of an established drug class but with a more predictable profile and kidney‑specific benefits, which has helped reshape the standard of care in lupus nephritis. Beyond this, the company is developing AUR200, a dual‑target biologic aimed at B‑cell pathways central to many autoimmune conditions, with plans to move into multiple disease areas. Management has shown a willingness to prioritize by discontinuing a less promising program to focus resources on its best assets. This concentrated R&D approach can be powerful if the lead pipeline program succeeds, but it also increases dependence on a small number of clinical bets, so trial outcomes and regulatory feedback will be crucial.

Summary

Aurinia has successfully transitioned from a purely developmental biotech into a small but profitable commercial company focused on autoimmune kidney disease. The income statement and cash flows now show early but real signs of sustainable operations, while the balance sheet remains reasonably healthy with modest debt and adequate, though not abundant, cash. Competitively, the company benefits from first‑in‑class oral therapy status, strong patents, and growing clinical evidence, but it is still heavily reliant on one main product and operates in a market where larger rivals are active. Its innovation engine is focused and promising, especially around AUR200, yet concentrated enough that pipeline setbacks would materially affect the outlook. Overall, Aurinia is in a more stable financial and commercial position than a typical early‑stage biotech, but its future still hinges on continued uptake of its flagship drug and successful execution of its limited but high‑impact R&D pipeline.

NEWS

November 4, 2025 · 6:00 AM UTC

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2025 and Provides Update on Recent Business Progress

Read more

November 3, 2025 · 6:00 AM UTC

Aurinia Pharmaceuticals to Report Financial Results for the Three and Nine Months Ended September 30, 2025 and Provide Update on Recent Business Progress on November 4, 2025

Read more

October 15, 2025 · 6:00 AM UTC

Aurinia Announces Upcoming Presentations of New Data on LUPKYNIS® at American College of Rheumatology Convergence and American Society of Nephrology Kidney Week 2025

Read more

September 29, 2025 · 8:27 PM UTC

Aurinia Responds to Now Retracted LinkedIn Post

Read more